비벤조디아제핀계 수면제 시장 보고서 : 동향, 예측 및 경쟁 분석(-2031년)

The future of the global non-benzodiazepine hypnotics market looks promising with opportunities in the hospital and clinic markets. The global non-benzodiazepine hypnotics market is expected to grow with a CAGR of 5.1% from 2025 to 2031. The major drivers for this market are the increasing pharmaceutical innovations, the growing awareness of mental health issues, and the rising healthcare expenditure.

• Lucintel forecasts that, within the type category, zolpidem is expected to witness the highest growth over the forecast period.
• Within the application category, hospital is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Non-benzodiazepine Hypnotics Market

The non-benzodiazepine hypnotics market is experiencing rapid growth driven by increasing demand for effective sleep aids with fewer side effects. As consumers seek safer alternatives to traditional benzodiazepines, innovative formulations and technological advancements are shaping the landscape. Regulatory changes and rising awareness about mental health are also influencing market dynamics. This evolving environment presents opportunities for new entrants and existing players to expand their product portfolios. The following key trends highlight the major developments transforming this market, reflecting shifts in consumer preferences, technological innovations, and regulatory landscapes that are redefining sleep disorder treatments globally.

• Growing Preference for Non-Addictive Sleep Aids: Increasing awareness of dependency issues associated with benzodiazepines has led consumers to favor non-benzodiazepine options. These drugs are perceived as safer, with lower addiction potential, driving demand. Healthcare providers are also recommending these alternatives for long-term use, which boosts market growth. The shift is supported by clinical research emphasizing safety profiles, making non-benzodiazepine hypnotics a preferred choice for managing insomnia and sleep disorders.
• Technological Innovations in Drug Delivery: Advances in drug delivery systems, such as controlled-release formulations and transdermal patches, are enhancing the efficacy and convenience of non-benzodiazepine hypnotics. These innovations improve patient compliance by reducing dosing frequency and minimizing side effects. Additionally, nanotechnology and novel delivery platforms are enabling targeted therapy, increasing drug bioavailability, and reducing adverse reactions. Such technological progress is expanding the therapeutic options available and improving overall treatment outcomes.
• Rising Adoption of Digital and Telehealth Solutions: The integration of digital health platforms and telemedicine is transforming how sleep disorders are diagnosed and managed. Remote consultations, sleep tracking devices, and mobile apps facilitate early diagnosis and personalized treatment plans. This trend increases accessibility, especially in remote or underserved areas, and supports ongoing monitoring of medication effectiveness. The digital shift is also fostering patient engagement and adherence, ultimately enhancing market penetration and expanding the reach of non-benzodiazepine hypnotics.
• Regulatory Changes and Market Approvals: Evolving regulatory frameworks are impacting the development and commercialization of non-benzodiazepine hypnotics. Governments and health authorities are emphasizing safety and efficacy, leading to stricter approval processes but also encouraging innovation. Recent approvals of novel compounds with improved safety profiles are boosting market confidence. Regulatory support for generic versions and biosimilars is also making these drugs more affordable and accessible, further fueling market expansion and encouraging investment in research and development.
• Increasing Focus on Personalized Medicine: The trend toward personalized treatment approaches is gaining momentum in the sleep disorder market. Genetic testing and biomarker analysis are being used to tailor therapies to individual patient profiles, improving efficacy and reducing side effects. This precision medicine approach is driving the development of targeted non-benzodiazepine hypnotics and combination therapies. It also encourages a shift from one-size-fits-all treatments to more customized solutions, enhancing patient outcomes and market competitiveness.

In summary, these trends are collectively reshaping the non-benzodiazepine hypnotics market by emphasizing safety, technological innovation, digital integration, regulatory support, and personalized care. This evolution is leading to more effective, accessible, and patient-centric sleep disorder treatments, positioning the market for sustained growth and innovation.

Recent Developments in the Non-benzodiazepine Hypnotics Market

The non-benzodiazepine hypnotics market has experienced significant growth driven by increasing awareness of sleep disorders, advancements in pharmaceutical research, and a shift towards safer sleep aids. As consumers seek alternatives to traditional benzodiazepines, pharmaceutical companies are innovating to meet this demand. Regulatory changes and the rising prevalence of insomnia and other sleep-related issues further propel market expansion. Technological advancements in drug delivery and formulation are also shaping the landscape. These developments collectively influence market dynamics, creating new opportunities and challenges for stakeholders. Understanding these key trends is essential for strategic planning and investment in this evolving sector.

• Rising Prevalence of Sleep Disorders: The increasing incidence of insomnia and other sleep disorders globally has driven demand for non-benzodiazepine hypnotics, leading to market growth. Patients prefer these medications due to their perceived safety and fewer side effects compared to traditional benzodiazepines, boosting sales and encouraging new product development.
• Innovation in Drug Formulations: Pharmaceutical companies are developing novel formulations such as extended-release tablets and sublingual options. These innovations improve patient compliance and convenience, enhancing therapeutic outcomes and expanding market reach. The focus on targeted delivery systems also reduces side effects, making these drugs more attractive.
• Regulatory Approvals and Guidelines: Regulatory agencies have streamlined approval processes for non-benzodiazepine hypnotics, facilitating faster market entry. Updated guidelines emphasize safety and efficacy, encouraging manufacturers to innovate while ensuring patient safety. This regulatory environment fosters competition and accelerates product launches.
• Technological Advancements: Advances in drug delivery technologies, including nanotechnology and bioavailability enhancement, have improved drug efficacy and reduced adverse effects. These innovations enable the development of more effective and safer sleep aids, thereby expanding the market and increasing consumer trust.
• Growing Awareness and Preference for Safer Alternatives: Increased awareness about the risks associated with benzodiazepines, such as dependency and cognitive impairment, has shifted consumer preference toward non-benzodiazepine options. This trend is supported by healthcare provider recommendations and public health campaigns, further fueling market growth.

In summary, these developments are collectively transforming the non-benzodiazepine hypnotics market by enhancing product safety, efficacy, and patient acceptance. The market is experiencing accelerated growth driven by innovation, regulatory support, and changing consumer preferences, positioning it for sustained expansion in the coming years.

Strategic Growth Opportunities in the Non-benzodiazepine Hypnotics Market

The non-benzodiazepine hypnotics market is experiencing rapid growth driven by increasing demand for effective sleep aids with fewer side effects. As consumers seek safer alternatives to traditional sedatives, key applications are expanding across healthcare sectors. This evolution presents significant opportunities for pharmaceutical companies to innovate and capture market share. Understanding these growth avenues is essential for stakeholders aiming to capitalize on emerging trends and improve patient outcomes. The following five key growth opportunities across different applications highlight the markets potential for expansion and increased profitability.

• Sleep Disorder Treatment: The growing prevalence of insomnia and sleep disturbances is fueling demand for non-benzodiazepine hypnotics. These medications offer effective sleep induction with reduced dependency risks, making them preferred options for long-term management. This trend enhances market growth by expanding the patient base and encouraging innovation in sleep therapy solutions.
• Psychiatric Care: Non-benzodiazepine hypnotics are increasingly used in psychiatric settings to manage anxiety and sleep issues associated with mental health disorders. Their favorable safety profile supports broader adoption among clinicians, leading to improved treatment adherence and patient outcomes. This application broadens the market scope within mental health treatment protocols.
• Geriatric Applications: The aging populations rising sleep problems create a significant demand for safe, non-addictive sleep aids. Non-benzodiazepine hypnotics are particularly suitable for elderly patients, reducing risks of falls and cognitive impairment. This opportunity drives market growth by addressing the needs of a vulnerable demographic with tailored solutions.
• Postoperative Recovery: Use of non-benzodiazepine hypnotics in surgical and postoperative care helps manage sleep disturbances caused by hospital stays and anesthesia effects. Their safety profile makes them ideal for short-term use, improving patient recovery experiences. This application enhances market penetration in hospital and surgical settings.
• Consumer Wellness and Over-the-Counter (OTC) Products: Increasing consumer awareness and preference for OTC sleep aids are expanding the market beyond prescription drugs. Non-benzodiazepine hypnotics are being formulated into OTC products, offering convenient, safe sleep solutions. This trend broadens market reach and stimulates sales in retail channels.

In summary, these growth opportunities are significantly impacting the non-benzodiazepine hypnotics market by expanding its application scope, attracting new customer segments, and fostering innovation. The increasing demand across healthcare and consumer sectors is driving market expansion, encouraging pharmaceutical development, and improving patient care outcomes. As these opportunities evolve, the market is poised for sustained growth and increased competitiveness.

Non-benzodiazepine Hypnotics Market Driver and Challenges

The non-benzodiazepine hypnotics market is influenced by a variety of technological, economic, and regulatory factors that shape its growth trajectory. Advances in pharmaceutical research and development have led to the creation of more effective and safer sleep aids, driving market expansion. Economic factors such as increasing healthcare expenditure and rising prevalence of sleep disorders further propel demand. Regulatory policies aimed at ensuring drug safety and efficacy also impact market dynamics, either facilitating or constraining growth. Additionally, technological innovations in drug delivery systems and formulations enhance product efficacy and patient compliance. These combined factors create a complex environment that influences market trends, opportunities, and challenges.

The factors responsible for driving the non-benzodiazepine hypnotics market include:

• Technological Advancements: The development of novel drug formulations and delivery systems, such as extended-release tablets and transdermal patches, improves drug efficacy and patient adherence. Innovations in pharmacology enable the creation of safer, more targeted sleep aids with fewer side effects, boosting market growth. Continuous research into new compounds and mechanisms of action also expands the product pipeline, attracting investments and fostering competition. These technological improvements meet the increasing demand for effective sleep solutions, especially among aging populations and those with chronic sleep disorders.
• Rising Prevalence of Sleep Disorders: The increasing incidence of insomnia and other sleep-related issues worldwide is a significant driver. Factors such as stress, lifestyle changes, aging populations, and comorbid conditions contribute to the growing need for effective sleep medications. As awareness about sleep health improves, more individuals seek treatment, leading to higher demand for non-benzodiazepine hypnotics, which are perceived as safer alternatives to traditional sedatives. This trend is particularly prominent in developed countries with advanced healthcare infrastructure, further fueling market expansion.
• Economic Growth and Healthcare Expenditure: Rising disposable incomes and increased healthcare spending in emerging and developed economies facilitate greater access to sleep disorder treatments. Insurance coverage and government healthcare programs support the affordability of prescription medications, encouraging patients to seek treatment. The growing focus on mental health and sleep health as part of overall wellness initiatives also contributes to increased market demand. As healthcare budgets expand, pharmaceutical companies are motivated to invest in research and marketing of non-benzodiazepine hypnotics, driving market growth.
• Regulatory Support and Approvals: Stringent regulatory frameworks ensure the safety and efficacy of sleep medications, fostering consumer confidence. Approval of new drugs by authorities such as the FDA and EMA accelerates market entry and product availability. Regulatory incentives for developing non-benzodiazepine hypnotics, including fast-track designations and orphan drug status, encourage innovation. Moreover, evolving guidelines favor the use of non-benzodiazepine options over traditional benzodiazepines due to their improved safety profiles, thus expanding market opportunities.
• Growing Awareness and Acceptance: Increased awareness about sleep health and the risks associated with traditional benzodiazepines promotes the adoption of non-benzodiazepine hypnotics. Educational campaigns by healthcare providers and pharmaceutical companies inform patients about safer alternatives, reducing stigma and encouraging treatment adherence. The shift towards personalized medicine and targeted therapies also enhances acceptance of newer sleep aids. This growing acceptance supports sustained market growth, especially as patients and clinicians prefer medications with fewer dependency risks and side effects.

The challenges facing this Market include:

• Stringent Regulatory Environment: While regulations ensure safety, they also pose barriers to market entry for new products. Lengthy approval processes, high compliance costs, and evolving standards can delay product launches and increase R&D expenses. Navigating complex regulatory landscapes across different regions adds to the challenge, potentially limiting innovation and market expansion. Companies must invest significant resources to meet regulatory requirements, which can impact profitability and slow down the introduction of new therapies.
• Side Effects and Safety Concerns: Despite being safer than benzodiazepines, non-benzodiazepine hypnotics are associated with adverse effects such as dependence, cognitive impairment, and sleep-related behaviors like sleepwalking. These safety concerns can lead to regulatory restrictions, recalls, and reduced consumer confidence. Managing these risks requires ongoing post-marketing surveillance and formulation improvements, which can increase costs and complicate market strategies. Public perception of safety issues may also hinder market growth and patient acceptance.
• Market Competition and Patent Expirations: The presence of numerous players and generic versions intensifies competition, leading to price pressures and reduced profit margins. Patent expirations of key drugs open the market to generics, further challenging brand-name manufacturers. Companies must continuously innovate to maintain market share, which involves substantial investment in R&D. Additionally, the emergence of alternative therapies and non-pharmacological treatments, such as cognitive-behavioral therapy, adds to the competitive landscape, potentially limiting the growth of pharmaceutical options.

In summary, the non-benzodiazepine hypnotics market is shaped by technological innovations, increasing sleep disorder prevalence, economic growth, regulatory support, and rising awareness. However, challenges such as regulatory hurdles, safety concerns, and intense competition pose significant obstacles. Overall, these factors collectively influence the markets growth potential, requiring stakeholders to navigate a complex environment to capitalize on emerging opportunities while managing risks effectively.

List of Non-benzodiazepine Hypnotics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies non-benzodiazepine hypnotics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the non-benzodiazepine hypnotics companies profiled in this report include-

• Sanofi-aventis
• Hikma Pharmaceuticals
• Northstar Rx
• Teva Pharmaceuticals
• Torrent Pharma
• Apotex
• Endo
• Mylan Pharmaceuticals
• Abbott
• Sun Pharmaceutical

Non-benzodiazepine Hypnotics Market by Segment

The study includes a forecast for the global non-benzodiazepine hypnotics market by type, application, and region.

Non-benzodiazepine Hypnotics Market by Type [Value from 2019 to 2031]:

• Zolpidem
• Zopiclone
• Zaleplon
• Others

Non-benzodiazepine Hypnotics Market by Application [Value from 2019 to 2031]:

• Hospital
• Clinic
• Others

Non-benzodiazepine Hypnotics Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Non-benzodiazepine Hypnotics Market

The non-benzodiazepine hypnotics market has experienced significant growth driven by increasing awareness of sleep disorders, advancements in pharmaceutical research, and a rising demand for safer sleep aids. Countries are adopting innovative formulations and expanding their healthcare infrastructure to meet the growing needs. Regulatory changes and technological innovations are also shaping the market landscape, leading to new product launches and strategic collaborations. As sleep health gains prominence globally, these developments reflect a shift towards more effective and safer solutions for insomnia and related conditions.

• United States: The US market has seen a surge in non-benzodiazepine hypnotic prescriptions, driven by rising insomnia prevalence and a preference for non-addictive options. Major pharmaceutical companies are investing in research to develop longer-lasting formulations and combination therapies. Regulatory agencies have approved new drugs with improved safety profiles, and telemedicine is facilitating easier access to sleep disorder treatments. Market players are also focusing on personalized medicine approaches, leveraging genetic data to optimize therapy outcomes.
• China: China's market is rapidly expanding due to increasing urbanization, lifestyle changes, and a growing awareness of sleep health. Local companies are innovating with herbal and traditional medicine-based sleep aids, integrating them with modern formulations. The government's focus on healthcare infrastructure and expanding insurance coverage is boosting market growth. Additionally, e-commerce platforms are playing a crucial role in increasing product accessibility, and collaborations with international firms are enhancing product quality and innovation.
• Germany: Germany's market is characterized by a strong emphasis on safety and efficacy, with stringent regulatory standards. There is a notable shift towards non-pharmacological interventions, such as cognitive-behavioral therapy, alongside medication. Pharmaceutical companies are developing novel non-benzodiazepine agents with fewer side effects. The country's focus on research and development is fostering innovations in drug delivery systems, including extended-release formulations. Increasing awareness about the risks of dependency is also influencing prescribing practices.
• India: India's non-benzodiazepine hypnotics market is witnessing rapid growth due to rising stress levels, urbanization, and increasing awareness of sleep disorders. Local manufacturers are introducing affordable formulations to cater to a large population segment. The government's initiatives to improve healthcare access and the expansion of healthcare infrastructure are supporting market growth. Additionally, traditional medicine practices are being integrated with modern pharmacology to develop holistic sleep solutions. The rise of online pharmacies is further facilitating product distribution.
• Japan: Japan's market is driven by an aging population with a high prevalence of sleep disturbances. There is a focus on developing non-benzodiazepine drugs with minimal side effects suitable for elderly patients. Regulatory agencies are encouraging the development of safer medications, leading to innovative drug formulations. The integration of digital health tools, such as sleep tracking devices, is enhancing treatment personalization. Market players are also investing in research to address comorbid conditions like anxiety and depression, which often coexist with sleep disorders.

Features of the Global Non-benzodiazepine Hypnotics Market

• Market Size Estimates: Non-benzodiazepine hypnotics market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Non-benzodiazepine hypnotics market size by type, application, and region in terms of value ($B).
• Regional Analysis: Non-benzodiazepine hypnotics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the non-benzodiazepine hypnotics market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the non-benzodiazepine hypnotics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the non-benzodiazepine hypnotics market by type (zolpidem, zopiclone, zaleplon, and others), application (hospital, clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Non-benzodiazepine Hypnotics Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Zolpidem : Trends and Forecast (2019-2031)
• 4.4 Zopiclone : Trends and Forecast (2019-2031)
• 4.5 Zaleplon : Trends and Forecast (2019-2031)
• 4.6 Others : Trends and Forecast (2019-2031)

5. Global Non-benzodiazepine Hypnotics Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital : Trends and Forecast (2019-2031)
• 5.4 Clinic : Trends and Forecast (2019-2031)
• 5.5 Others : Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Non-benzodiazepine Hypnotics Market by Region

7. North American Non-benzodiazepine Hypnotics Market

• 7.1 Overview
• 7.2 North American Non-benzodiazepine Hypnotics Market by Type
• 7.3 North American Non-benzodiazepine Hypnotics Market by Application
• 7.4 The United States Non-benzodiazepine Hypnotics Market
• 7.5 Canadian Non-benzodiazepine Hypnotics Market
• 7.6 Mexican Non-benzodiazepine Hypnotics Market

8. European Non-benzodiazepine Hypnotics Market

• 8.1 Overview
• 8.2 European Non-benzodiazepine Hypnotics Market by Type
• 8.3 European Non-benzodiazepine Hypnotics Market by Application
• 8.4 German Non-benzodiazepine Hypnotics Market
• 8.5 French Non-benzodiazepine Hypnotics Market
• 8.6 Italian Non-benzodiazepine Hypnotics Market
• 8.7 Spanish Non-benzodiazepine Hypnotics Market
• 8.8 The United Kingdom Non-benzodiazepine Hypnotics Market

9. APAC Non-benzodiazepine Hypnotics Market

• 9.1 Overview
• 9.2 APAC Non-benzodiazepine Hypnotics Market by Type
• 9.3 APAC Non-benzodiazepine Hypnotics Market by Application
• 9.4 Chinese Non-benzodiazepine Hypnotics Market
• 9.5 Indian Non-benzodiazepine Hypnotics Market
• 9.6 Japanese Non-benzodiazepine Hypnotics Market
• 9.7 South Korean Non-benzodiazepine Hypnotics Market
• 9.8 Indonesian Non-benzodiazepine Hypnotics Market

10. ROW Non-benzodiazepine Hypnotics Market

• 10.1 Overview
• 10.2 ROW Non-benzodiazepine Hypnotics Market by Type
• 10.3 ROW Non-benzodiazepine Hypnotics Market by Application
• 10.4 Middle Eastern Non-benzodiazepine Hypnotics Market
• 10.5 South American Non-benzodiazepine Hypnotics Market
• 10.6 African Non-benzodiazepine Hypnotics Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Non-benzodiazepine Hypnotics Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Sanofi-aventis
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Hikma Pharmaceuticals
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Northstar Rx
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Teva Pharmaceuticals
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Torrent Pharma
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Apotex
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Endo
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Mylan Pharmaceuticals
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Abbott
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Sun Pharmaceutical
  • Company Overview
  • Non-benzodiazepine Hypnotics Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us